| Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials RC Doebele, A Drilon, L Paz-Ares, S Siena, AT Shaw, AF Farago, ... The Lancet Oncology 21 (2), 271-282, 2020 | 1355 | 2020 |
| An update on larynx cancer CE Steuer, M El‐Deiry, JR Parks, KA Higgins, NF Saba CA: a cancer journal for clinicians 67 (1), 31-50, 2017 | 675 | 2017 |
| Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients J Remon, CE Steuer, SS Ramalingam, E Felip Annals of Oncology 29, i20-i27, 2018 | 220 | 2018 |
| Tumor mutation burden: leading immunotherapy to the era of precision medicine? CE Steuer, SS Ramalingam Journal of clinical oncology: official journal of the American Society of …, 2018 | 194 | 2018 |
| Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer PA Jänne, C Baik, WC Su, ML Johnson, H Hayashi, M Nishio, DW Kim, ... Cancer discovery 12 (1), 74-89, 2022 | 164 | 2022 |
| The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced‐stage cancer treated with immunotherapy MA Bilen, DJ Martini, Y Liu, C Lewis, HH Collins, JM Shabto, M Akce, ... Cancer 125 (1), 127-134, 2019 | 129 | 2019 |
| An update on the immune landscape in lung and head and neck cancers JW Carlisle, CE Steuer, TK Owonikoko, NF Saba CA: a cancer journal for clinicians 70 (6), 505-517, 2020 | 114 | 2020 |
| MAST1 drives cisplatin resistance in human cancers by rewiring cRaf-independent MEK activation L Jin, J Chun, C Pan, D Li, R Lin, GN Alesi, X Wang, HB Kang, L Song, ... Cancer cell 34 (2), 315-330. e7, 2018 | 108 | 2018 |
| Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium CE Steuer, M Behera, L Berry, S Kim, M Rossi, G Sica, TK Owonikoko, ... Cancer 122 (5), 766-772, 2016 | 104 | 2016 |
| Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy MA Bilen, JM Shabto, DJ Martini, Y Liu, C Lewis, H Collins, M Akce, ... Bmc Cancer 19, 1-8, 2019 | 102 | 2019 |
| Comparison of concurrent use of thoracic radiation with either carboplatin-paclitaxel or cisplatin-etoposide for patients with stage iii non–small-cell lung cancer: A … CE Steuer, M Behera, V Ernani, KA Higgins, NF Saba, DM Shin, ... JAMA oncology 3 (8), 1120-1129, 2017 | 102 | 2017 |
| Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial D Adkins, J Ley, P Neupane, F Worden, AG Sacco, K Palka, ... The lancet oncology 20 (9), 1295-1305, 2019 | 99 | 2019 |
| A phamacoeconomic analysis of personalized dosing vs fixed dosing of pembrolizumab in firstline PD-L1-positive non–small cell lung cancer DA Goldstein, N Gordon, M Davidescu, M Leshno, CE Steuer, N Patel, ... JNCI: Journal of the National Cancer Institute 109 (11), djx063, 2017 | 99 | 2017 |
| Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis MM Awad, GC Leonardi, S Kravets, SE Dahlberg, A Drilon, SA Noonan, ... Lung Cancer 133, 96-102, 2019 | 92 | 2019 |
| Atypical carcinoid tumor of the lung: a surveillance, epidemiology, and end results database analysis CE Steuer, M Behera, S Kim, Z Chen, NF Saba, RN Pillai, TK Owonikoko, ... Journal of Thoracic Oncology 10 (3), 479-485, 2015 | 85 | 2015 |
| Lung adenocarcinoma staging using the 2011 IASLC/ATS/ERS classification: a pooled analysis of adenocarcinoma in situ and minimally invasive adenocarcinoma M Behera, TK Owonikoko, AA Gal, CE Steuer, S Kim, RN Pillai, FR Khuri, ... Clinical lung cancer 17 (5), e57-e64, 2016 | 83 | 2016 |
| Pulmonary sarcomatoid carcinoma: an analysis of the national cancer data base CE Steuer, M Behera, Y Liu, C Fu, TW Gillespie, NF Saba, DM Shin, ... Clinical Lung Cancer 18 (3), 286-292, 2017 | 77 | 2017 |
| The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer CE Steuer, FR Khuri, SS Ramalingam Cancer 121 (8), E1-E6, 2015 | 77 | 2015 |
| ALK‐positive non–small cell lung cancer: Mechanisms of resistance and emerging treatment options CE Steuer, SS Ramalingam Cancer 120 (16), 2392-2402, 2014 | 68 | 2014 |
| Lung stereotactic body radiation therapy and concurrent immunotherapy: a multicenter safety and toxicity analysis S Tian, JM Switchenko, ZS Buchwald, PR Patel, JW Shelton, SE Kahn, ... International Journal of Radiation Oncology* Biology* Physics 108 (1), 304-313, 2020 | 66 | 2020 |
